More than 1,000 women a year with advanced cancer could benefit from capivasertib which can slow the disease.

In trials, in 708 women, when combined with hormone therapy, the drug doubled the time the cancer took to grow, from 3.6 months to 7.3 months, and shrank tumours in 23% of patients.